General Information

Venue
The workshop takes place at the:

**Holiday Inn St. Petersburg Moskovskye Vorota Hotel**
Moskovsky prospekt 97A
Saint Petersburg, 196084
Russia

Language
The official language of the workshop is English.

Scientific secretariat
Serono Symposia International Foundation
Salita di San Nicola da Tolentino, 1/b
00187 Rome, Italy
Senior Project Manager: Francesca Pellegrino
Tel.: +39 (0)6 420 413 511
Fax: +39 (0)6 420 413 677
E-mail: info@seronosymposia.org

Serono Symposia International Foundation is a Swiss Foundation with headquarters in 14, rue du Rhône, 1204 Geneva, Switzerland

Organizing secretariat
Meridiano Congress International
Via Mentana, 2/B - 00185 Rome, Italy
Senior Project Manager: Sara Guglielmini
T +39 (0)6 88 595 211
F +39 (0)6 88595 234
E-mail: s.guglielmini@meridiano.it
MTTC Medical Education Initiative
13th International Workshop

Aim of the meeting
The Medical Education Initiative on Molecular Targeted Therapy of Cancer (MTTC), established in 2001 and headed by the International Education Council (IEC), was developed to provide high quality medical education programs for medical oncologists. Starting from the 1st MTTC International Workshop held in 2002, the IEC created, in the form of a Core Educational Curriculum, the scientific platform for future medical education activities with the intent of regularly update the Core Curriculum through all MTTC activities worldwide.

The Core Educational Curriculum comprises four modules depending on the various strategies for targeted therapy, which are:
• Antibody-Based Therapy
• Signal Transduction Inhibition
• Immunotherapy
• Angiogenesis Inhibition

During this workshop, worldwide recognized oncology experts from different disciplines will present the basic mode of action and clinical application of various targeted therapies and will present the latest developments in molecular cell biology in relation to targeted cancer therapy.

Learning objectives
After attending this workshop, the participants will have an updated knowledge on:
• The basics of signal transduction, immunotherapy and angiogenesis with regard to cancer therapy
• New approaches in targeting cancer
• The latest developments in molecular cell biology in relation to targeted cancer therapy
• The current issues in active and passive immunotherapy
• Resistance to targeted therapy
• Rationale of novel combination

Target audience
Oncologists, radiation-oncologists, surgeons, pathologists.

Accreditation
The “13th MTTC International Workshop” (St. Petersburg - 4-5 May 2012) has been accredited with 10 (ten) ESMO-MORA points Category 1.

follow us on
SSIF_Oncology
http://twitter.com/SSIF_Oncology

All Serono Symposia International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted.
Scientific Organizers

Heinz Zwierzina
Chairman of the International Education Council (IEC)
Innsbruck Medical University
Innsbruck, Austria

Vladimir Fyodorovich Semiglazov
N.N. Petrov Research Institute of Oncology
S. Petersburg, Russia

International Education Council (IEC)

Jean Pierre Armand
Institut Curie
Paris, France

Wolfgang E. Berdel
Westfälische Wilhelms-Universität
Münster, Germany

Carsten Bokemeyer
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Markus Borner
Hospital Center Biel and University of Bern
Bern, Switzerland

Fortunato Ciardiello
Second University of Naples
Naples, Italy

Anthony TC Chan
Department of Clinical Oncology
Prince of Wales Hospital
HK Cancer Institute and Sir YK Pao Centre for Cancer
Hong Kong, China

Leif Håkansson
Linköping University Hospital
Linköping, Sweden

Stan Kaye
Royal Marsden Hospital
Drug Development and Gynaecology Units
Sutton, Surrey, UK

Håkan Mellstedt
Cancer Centre Karolinska
Karolinska University Hospital
Stockholm, Sweden

Salvatore Siena
The Falck Division of Oncology
Niguarda Ca’ Granda Hospital
Milan, Italy

Jean-Charles Soria
Institut Gustave Roussy
Villejuif, France

Josep Tabernero
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology [VHIO]
Barcelona, Spain

Carlos Vallejos
Instituto Nacional de Enfermedades Neoplásticas
Lima, Peru

Eric Van Cutsem
University Hospital Gasthuisberg
Leuven, Belgium

Yosef Yarden
Weizmann Institute of Science
Department of Biological Regulation
Rehovot, Israel

Christoph C. Zielinski
Comprehensive Cancer Center, Vienna
General Hospital and Medical University of Vienna
Vienna, Austria

Central European Cooperative Oncology Group (CECOG)

Heinz Zwierzina
Chairman of the International Education Council (IEC)
Innsbruck Medical University
Innsbruck, Austria
Friday - May 4, 2012

8.00 Registration

Welcome and Introduction
Chairmen: H. Zwierzina, Austria - V. Semiglazov, Russia

9.00 Introduction to the Medical Education Initiative on Molecular Targeted Therapy of Cancer
H. Zwierzina, Austria - V. Semiglazov, Russia

9.10 Lifetime Achievement Award
J.P. Allison, USA

9.50 L1 Basics of Signal Transduction
Y. Yarden, Israel

10.20 Discussion

10.40 Coffee break

Session I Inhibition of EGFR Family Pathways: Activity and Resistance
Chairmen: W.E. Berdel, Germany - L. Håkansson, Sweden

11.00 L2 Targeting EGFR with Monoclonal Antibodies
E. Van Cutsem, Belgium

11.25 L3 Targeting EGFR with Tyrosine Kinase Inhibitors
V. Moiseyenko, Russia

11.50 L4 HER2/neu: Antibodies and Small Molecules
M. Borner, Switzerland

12.15 Discussion

12.35 Lunch break

Session II New Targets
Chairmen: V. Semiglazov, Russia - M. Borner, Switzerland

13.35 L5 PI3K-Akt-mTOR Pathway Inhibitors
J.P. Armand, France

14.00 L6 RAF and MEK Inhibitors
J. Tabernero, Spain

14.25 L7 Non-EGFR Family Membrane Receptors
J. Tabernero, Spain

14.50 L8 Epigenetic Therapy and Synthetic Lethality with PARP Inhibitors
S. Kaye, UK

15.15 Discussion

15.45 Coffee Break

Session III Inhibition of Angiogenesis: Activity and Resistance
Chairmen: S. Kaye, UK - V. Moiseyenko, Russia

16.10 L9 Role of Angiogenesis Inhibition in Cancer
W.E. Berdel, Germany

16.40 L10 Antiangiogenic Drugs in Clinical Practice
J.P. Armand, France

17.10 Discussion

17.30 End of the first day
Saturday - May 5, 2012

**Session I: Current Issues in Active and Passive Immunotherapy**

**Chairmen:** S. Siena, Italy - Y. Yarden, Israel

- **8.15 L11** Immunoregulation in Cancer  
  L. Håkansson, Sweden

- **8.35 L12** Immunoregulation in the clinic  
  C. Zielinski, Austria

- **8.55 L13** Passive Immunotherapy with Monoclonal Antibodies  
  H. Zwierzina, Austria

- **9.15 L14** Cancer Immunotherapy and Prophylactic Cancer Vaccines  
  H. Mellstedt, Sweden

- **9.35** Discussion

- **9.55** Coffee break

**Session II: Emerging perspectives**

**Chairmen:** H. Mellstedt, Sweden - C. Zielinski, Austria

- **10.15 L15** Biomarkers in solid tumors: the pathologist perspective  
  F. Penault-Llorca, France

- **10.35 L16** Biomarkers in solid tumors: the clinicians’ perspective  
  S. Siena, Italy

- **10.55 L17** Rationale of Combination Therapy  
  H. Zwierzina, Austria

- **11.15 L18** New Drugs – New Side Effects  
  J. Tabernero, Spain

- **11.35** Discussion

**New Targeted Therapies in Selected Indications (Overview and Case Discussion)**

**Chairmen:** E. Van Cutsem, Belgium - J.P. Armand, France

**Molecular Targeted Therapy in:**

- **11.55** Breast Cancer  
  C. Zielinski, Austria

- **12.10** Colorectal Cancer  
  S. Siena, Italy

- **12.25** Non-Small Cell Lung Cancer  
  W.E. Berdel, Germany

- **12.40** Melanoma  
  M. Borner, Switzerland

- **12.55** Gynecological Cancer  
  S. Kaye, UK

- **13.10** Closing Remarks

- **13.15** End of the workshop
Workshop Faculty

James P. Allison  
Ludwig Center for Cancer Immunotherapy  
Immunology Program  
David H. Koch Immunologic Studies  
Howard Hughes Medical Institute  
Department of Medicine  
Memorial Sloan-Kettering Cancer Center  
New York City, NY, USA

Jean Pierre Armand  
Institut Curie  
Paris, France

Wolfgang E. Berdel  
Westfälische Wilhelms-Universität  
Münster, Germany

Markus Borner  
Hospital Center Biel  
and University of Bern  
Bern, Switzerland

Leif Håkansson  
Linköping University Hospital  
Linköping, Sweden

Stan Kaye  
Royal Marsden Hospital  
Drug Development and Gynaecology Units  
Sutton, Surrey, UK

Håkan Mellstedt  
Cancer Centre Karolinska  
Karolinska University Hospital  
Stockholm, Sweden

Vladimir M. Moiseyenko  
Oncology department  
Diagnostic and Treatment Center under  
International Institute for Biological Systems  
named after S.M. Berezin  
St. Petersburg, Russia

Frédérique Penault-Llorca  
Centre Jean-Perrin  
Pathology Department  
Clermont-Ferrand, France

Vladimir Fyodorovich Semiglazov  
N.N. Petrov Research Institute of Oncology  
St. Petersburg, Russia

Salvatore Siena  
The Falck Division of Oncology  
Niguarda Ca´ Granda Hospital  
Milan, Italy

Josep Tabernero  
Vall d’Hebron University Hospital  
Vall d’Hebron Institute of Oncology (VHIO)  
Barcelona, Spain

Eric Van Cutsem  
University Hospital Gasthuisberg  
Leuven, Belgium

Yosef Yarden  
Weizmann Institute of Science  
Department of Biological Regulation  
Rehovot, Israel

Christoph C. Zielinski  
Comprehensive Cancer Center, Vienna  
General Hospital and Medical University of Vienna  
Vienna, Austria  
Central European Cooperative Oncology Group (CECOG)

Heinz Zwierzina  
Chairman of the  
International Education Council (IEC)  
Innsbruck Medical University  
Innsbruck, Austria
All Serono Symposia International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. All Serono Symposia International Foundation programs are made possible thanks to educational grants received from: Celgene, Centre d’Esclerosi Múltiple de Catalunya, ComtecMed, Congrex Sweden, Congrex Switzerland, Cryo-Save, Datanalysis, Esaote, European Society of Endocrinology, Fondazione Humanitas, Fundación IVI, ISF P International Society for Fertility Preservation, ISMH International Society of Men’s Health, K.I.T.E., Merck Serono, Sanofi-Aventis, University of Catania, Vall d’Hebron University Hospital.

The MTTC International Education Council makes a special thanks to:

Merck Serono

MERCK

Celgene

Committed to improving the lives of patients worldwide®